Cytokinetics, IncorporatedCYTKNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank51
Year-over-Year Change
Year-over-year operating income growth rate
Latest
-6.96%
↑ 86% vs avg
Percentile
P51
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
-49.73%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -6.96% |
| Q3 2025 | -49.55% |
| Q2 2025 | 28.35% |
| Q1 2025 | -11.93% |
| Q4 2024 | 1.25% |
| Q3 2024 | -8.17% |
| Q2 2024 | -3.12% |
| Q1 2024 | 0.93% |
| Q4 2023 | -4.21% |
| Q3 2023 | -0.18% |
| Q2 2023 | 1.95% |
| Q1 2023 | 2.01% |
| Q4 2022 | -17.14% |
| Q3 2022 | -897.25% |
| Q2 2022 | 86.03% |
| Q1 2022 | -258.72% |
| Q4 2021 | 68.64% |
| Q3 2021 | -26.29% |
| Q2 2021 | -34.93% |
| Q1 2021 | -11.55% |
| Q4 2020 | -802.30% |
| Q3 2020 | 116.02% |
| Q2 2020 | -6.57% |
| Q1 2020 | -28.08% |
| Q4 2019 | 0.92% |
| Q3 2019 | 10.44% |
| Q2 2019 | -8.96% |
| Q1 2019 | -14.26% |
| Q4 2018 | -19.79% |
| Q3 2018 | 23.49% |
| Q2 2018 | 10.40% |
| Q1 2018 | 28.46% |
| Q4 2017 | -28.51% |
| Q3 2017 | -12.82% |
| Q2 2017 | -8.36% |
| Q1 2017 | -402.43% |
| Q4 2016 | -76.34% |
| Q3 2016 | 395.07% |
| Q2 2016 | 7.89% |
| Q1 2016 | -32.51% |